Strategies for high-throughput analysis of interactions between various hormones and drugs with the estrogen receptor (ER) are crucial for accelerating the understanding of ER biology and pharmacology. Through careful analyses of the crystal structures of the human ER (hER) ligand-binding domain (hER-LBD) in complex with different ligands, we hypothesized that the hER-LBD intramolecular folding pattern could be used to distinguish ER agonists from selective ER modulators and pure antiestrogens. We therefore constructed and validated intramolecular folding sensors encoding various hER-LBD fusion proteins that could lead to split Renilla͞firefly luciferase reporter complementation in the presence of the appropriate ligands. A mutant hER-LBD with low affinity for circulating estradiol was also identified for imaging in living subjects. Cells stably expressing the intramolecular folding sensors expressing wild-type and mutant hER-LBD were used for imaging ligand-induced intramolecular folding in living mice. This is the first hER-LBD intramolecular folding sensor suited for high-throughput quantitative analysis of interactions between hER with hormones and drugs using cell lysates, intact cells, and molecular imaging of small living subjects. The strategies developed can also be extended to study and image other important protein intramolecular folding systems.
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complementation ͉ optical imaging ͉ split reporters E strogens are responsible for the growth, development, and maintenance of the reproductive, skeletal, neuronal, and immune systems as well as and other systems. The physiological effects of these hormones are mediated by the estrogen receptor (ER), which is a ligand-inducible nuclear transcription factor (1) . In the classical pathway of steroid hormone action, 17␤-estradiol (E2), hormones, and a variety of other estrogens bind to the ligandbinding domain (LBD) of ER and lead to its dimerization and subsequent binding to a specific regulatory sequence in the promoters of ER target genes known as the estrogen response elements (2, 3) , which then trigger activation or repression of many downstream target genes (4) . The deficiency or excess of estrogens can lead to various pathological conditions including osteoporosis and breast carcinomas (5), making ER a major cellular therapeutic target.
Elegant crystallographic studies with ER-LBD have shown that conformation of helix 12 (H12) is critical in responses observed with various ER ligands (4, 6, 7) . The conformation of H12 behaves as a ''molecular switch'' that either prevents or enhances ER from binding to an array of coactivator proteins, which then activates transcription of many downstream estrogen-regulated genes responsible for cell growth. Given the critical role of H12 in ER signaling, we reasoned that it may be feasible to develop an intramolecular ER folding sensor with specific split reporter complementation patterns to study ligand pharmacology based directly on the conformational changes of H12 in response to different ligands (Fig. 1) .
We used a split synthetic Renilla luciferase (RLUC) and firefly luciferase (FLUC) complementation system, which we previously developed and validated (8, 9) , to test this hypothesis by assaying ligand-induced RLUC͞FLUC complementation in cell lysates, intact cells, and cell implants in living mice by noninvasive bioluminescence optical imaging. The validated ER intramolecular folding sensors can also be used to distinguish ligand pharmacology in cell culture studies and cell implants in living animals treated with different ER ligands, agonists, selective ER modulators (SERMs), and pure antiestrogens. Moreover, a mutant human ER (hER) with low affinity to E2 was identified and used as an ER sensor for characterization of ER ligand interaction in living mice without significant competition from endogenous circulating estrogens.
Author contributions: R.P. and S.S.G. designed research; R.P. performed research; R.P. and S.S.G. analyzed data; and R.P. and S.S.G. wrote the paper.
The authors declare no conflict of interest.
Abbreviations: RLUC, Renilla luciferase; FLUC, firefly luciferase; N-RLUC, N-fragment of RLUC gene; C-RLUC, C-fragment of RLUC gene; ER, estrogen receptor; hER, human ER; LBD, ligand-binding domain; SERM, selective ER modulator; DES, diethylstilbestrol; 4-OHT, 4-hydroxytamoxifen; E2, 17␤-estradiol; H12, helix 12; ICI, ICI182,780. *To whom correspondence may be addressed. E-mail: paulmur8@stanford.edu or sgambhir@stanford.edu.
© 2006 by The National Academy of Sciences of the USA
Fig. 1.
Schematic representation of the hypothetical model of ligandinduced intramolecular folding of ER that leads to split RLUC complementation. The N-and C-terminal fragments of split RLUC were fused to the N and C terminus, respectively, of the hER␣ of various lengths (amino acids 281-549 and 281-595). Binding of ER ligands to the intramolecular folding sensor (N-RLUC-hER-C-RLUC) induces different potential folding patterns in the LBD based on the type of ligand. This folding leads to split RLUC complementation for ER antagonist (b) (H12 and ligands are colored green), low complementation for ER agonist (a) (H12 and ligands are colored blue), and no complementation for partial ER agonist͞antagonist (c) (H12 and ligands are colored gold) with the selective folding sensor. Even though the distance between the N-and C-RLUC fragments after binding with partial agonist (c) is smaller than that of agonists (b), this model depicts the importance of the orientations of the split RLUC fragments in complementation. The yellow spheres are hydrophobic amino acids located between helix 3 and helix 5 of LBD.
Results

RLUC Complementation as Sensors of ER Ligand-Induced Intramolec-
ular Folding. Several factors need to be considered to achieve efficient ligand-induced split RLUC complementation, and also ligand-induced complementation that distinguishes agonists from antagonists. Key factors include (i) the distance between the complementing N-and C-RLUC fragments in the intramolecular folding sensor before and after the binding of ligands, (ii) the orientation of N-and C-RLUC fragments after binding of different ER ligands, and (iii) the position of RLUC fragments in recovering the substrate binding pockets through complementation after ligand binding. By carefully considering these factors along with the crystal structures of different ER ligand complexes (bound with agonists, SERMs, and pure antiestrogens) and the importance of H12 within the LBD, we constructed a series of vectors that expresses fusion proteins with split RLUC fragments and different portions of the hER (Fig. 2a) (4, 10) . We also confirmed the orientation of split RLUC fragments needed for efficient complementation (Fig. 6 , which is published as supporting information on the PNAS web site). All of these vectors were studied in 293T cells (ER-negative cells, transiently transfected with ER) treated with several ER ligands, including E2, tamoxifen, raloxifene, genistein, diethylstilbestrol (DES), and 4-hydroxytamoxifen (4-OHT) (structures of ligands are in Fig. 7 , which is published as supporting information on the PNAS web site). Among the different portions of hER examined, the fusion protein containing hER of amino acids 281-595 [hER : partial hinge (domain D), LBD (domain E), and domain F] showed a significant level of ligand-induced RLUC complementation for both agonists and SERMs. The hER␣ was used for constructing all vectors in this study. The level of complementation achieved by this fusion protein with both SERMs and agonists was 80 Ϯ 15 times greater than in cells exposed to carrier controls (P Ͻ 0.001). The cells exposed with genistein, a very-low-affinity ER␣ agonist, showed no complementation, similar to untreated cells (Fig. 2b) . At the same time, the cells transfected with the vector expressing the fusion protein containing amino acids 281-549 of hER (hER : domains D and E) show complementation that clearly distinguishes agonists from SERMs. In transfected cells treated with SERMs and agonists, 80-fold Ϯ 15-fold and 15-fold Ϯ 5-fold increases in complementation were observed, respectively, relative to untreated cells (P Ͻ 0.05) (Fig. 2c) .
Up-regulation of the multidrug-resistant P-glycoprotein by ER ligands and associated change in the signal by coelenterazine (11) were ruled out by different experiments in cell lysates and intact cells (Fig. 8 , which is published as supporting information on the PNAS web site).
Complementation of ER-LBD Intramolecular Folding
Sensor Is Independent of the Levels of Endogenous ER␣ Expression. To determine whether ligand-induced hER intramolecular-folding-assisted RLUC complementation in transfected 293T cells is due to increased protein expression of the folding sensor N-RLUC-hER 281-549-C-RLUC, Western blot analysis was performed by using the RLUC antibody before and after treatment with different ER ligands. Treatment of 293T cells with E2, DES, genistein, and raloxifene did not lead to significant changes in the protein level of the folding sensor ( Fig. 2d Inset Lower). Interestingly, even though the levels of sensor protein were significantly reduced in the transfected cells treated with the SERM tamoxifen and two anticancer drugs, epigallocatechin gallate and cisplatin (both non-ER ligands), the RLUC signal in tamoxifen-treated cells was still significantly greater than that in the cells treated with the agonists E2 and DES (P Ͻ 0.05) (Fig. 2d) . The anticancer drugs did not lead to any RLUC signal, compared with carrier control-treated cells (P Ͼ 0.05). These results show that the variations in the RLUC activity in the cells treated with different ligands were not mediated through changes in the level of sensor protein but were more likely to be caused by different complementation patterns within the receptor induced by the ligands. The ER␣ protein level in transfected MCF-7 cells was also estimated with Western blot analysis before and after the cells were treated with different ER ligands. Treatment of MCF-7 cells with ER ligands did not lead to significant changes in the intracellular ER␣ protein levels ( Fig. 2d Inset Upper). Also, ligand-induced intramolecular folding of ER studied in different ER-positive (MCF-7) and ER-negative (MDA-MB-231 and 293T) cell lines showed no significant relation with the intracellular ER level ( Fig. 3 d-f ). 
Time-and Dose-Dependent Induction of hER-LBD Intramolecular RLUC
Complementation. To determine the kinetics of ligand-induced RLUC complementation, 293T cells transiently transfected to express the fusion protein N-RLUC-hER 281-549 -C-RLUC were exposed to 1 M of three representative ligands (the agonists E2 and DES and the SERM 4-OHT) and assayed for complemented RLUC activity at 6, 12, 18, and 24 h. The results showed significant levels of RLUC complementation in transfected cells exposed to the 4-OHT at all time points studied (P Ͻ 0.002 relative to carrier control-treated͞untreated cells). The agonists E2 and DES led to RLUC complementation that was significantly lower than 4-OHT but higher than that of carrier control͞untreated cells at all time points studied (P Ͻ 0.001). Furthermore, the maximum level of ligand-induced RLUC complementation was achieved after 18 h of exposure to ligands (Fig. 4a) . The potency of each ligand to induce RLUC complementation in transiently transfected 293T cells expressing N-RLUC-hER 281-549 -C-RLUC was studied at different ligand concentrations with RLUC activities determined by luminometer assays. A dose-dependent increase in complemented RLUC activity was observed in all cases, with maximum induction at 1 M except for the agonist DES, which showed maximum activity at 1.5 M relative to carrier control-treated͞untreated cells (Fig. 4b) .
Competitive Binding of ER Agonists and SERMs in Ligand-Induced
Intramolecular-Folding-Assisted RLUC Complementation. To study ER intramolecular folding in living mice, the 293T cells were stably transfected to express the intramolecular folding sensor N-RLUChER 281-549 -C-RLUC. No significant difference in RLUC activity was observed between the stable and transiently transfected cells with all ligands studied (data not shown). These stable cells were used for studying the competitive binding of an agonist (E2) and a SERM (tamoxifen) in inducing RLUC complementation. The cells were assayed for complemented RLUC activity 18 h after being simultaneously exposed to a fixed concentration of E2 (1 M) with various concentrations of tamoxifen (0.008-1 M). Similarly, stable cells expressing the intramolecular folding sensor were exposed to a fixed concentration of tamoxifen (1 M) and various concentrations of E2 (0.008-1 M). E2-induced complemented RLUC activity was significantly enhanced in the presence of tamoxifen (P Ͻ 0.05) (Fig. 4c) , and the tamoxifen-induced complemented RLUC activity was reduced in the presence of E2 (P Ͻ 0.05) (Fig. 4d) . The drug ICI is a pure antiestrogen (Fig. 3a) that is currently in clinical use for the treatment of both ER-positive and ER-negative breast cancers (12, 13) . Crystallographic studies with ER␤͞pure antiestrogen complex suggest unique structural features of this receptor complex leading to its interesting pharmacology (14) . In our system with 293T cells transfected to express the sensors RLUC-ER (281-549) or RLUC-ER (281-595), ICI led to dosedependent RLUC complementation with maximum induction at 0.25 M (Fig. 3b) . Furthermore, RLUC complementation induced by ICI was distinct from that of ER SERMs or agonists (Fig. 3f ) . It is of note that no significant degradation of the fusion sensor protein was observed in transfected 293T cells in the presence of ICI (Fig. 3c) (15) . Binding of endogenous E2 to the intramolecular folding sensor in living animals will limit its use in tumor models or a transgenic model for studying hER interactions with ligands and drugs. Hence, to overcome this issue, we generated single amino acid mutations at position 521 of hER␣ that are analogous to the mutation generated in mouse ER␣ at amino acid position 525 (G525R), which was reported to reduce affinity to E2 by 1,000-fold Table 1 , which is published as supporting information on the PNAS web site. Among all of the mutations created at position 521, the glycine-to-threonine (G521T) transition led to a 94% reduction in the intramolecular folding-mediated RLUC complementation induced by E2 (P Ͻ 0.001); an only 12-22% reduction for DES, 4-OHT, and raloxifene (P Ͻ 0.05); and no significant changes in response to genistein and ICI (P Ͻ 0.05) (Fig. 9 , which is published as supporting information on the PNAS web site). The sensor with mutant hER (N-RLUC-hER 281-549/G521T -C-RLUC), which distinguishes ER antagonists from SERMs (Fig. 2d) , and the sensor with mutant mouse ER (N-RLUC-mER 281-549/G525R -C-RLUC) were transiently transfected into 293T cells and treated with different ER ligands, and RLUC complementation was determined by luminometer assay. Our folding sensor with mutant hER (G521T) appeared less sensitive to the endogenous ligand E2 and retained more of the DES and raloxifene effects compared with the folding sensor with the mutant mER (G525R) (Fig. 10 , which is published as supporting information on the PNAS web site).
The ER Intramolecular Folding System with LBDs ER281-549͞G521G, ER281-549͞G521T, and ER281-595͞G521G Using Split FLUC Enzyme
Fragments. To evaluate the ER intramolecular folding system's utility and generalizability, we also constructed vectors with improved split FLUC fragments (our unpublished data) with different ER constructs and various ligands (Fig. 11 , which is published as supporting information on the PNAS web site). The results show similar patterns as achieved when using the corresponding system with split RLUC fragments (Fig. 12 , which is published as supporting information on the PNAS web site).
Imaging of ER Intramolecular Folding in Living Mice.
We studied the interactions between hER with ligands in living mice using the ER intramolecular folding-mediated RLUC complementation system, by implanting 293T cells stably expressing wild-type (N-RLUChER 281-549 -C-RLUC) or mutant (N-RLUC-hER 281-549/G521T -C-RLUC) hER sensor on either side in the lower back of female nude mice (n ϭ 3). Bioluminescence imaging of RLUC activity was performed immediately after cell implantations and 18 h after i.p. injection of raloxifene (0.5 mg). There was no significant difference in RLUC complementation induced by the SERMs 4-OHT and raloxifene in different experiments; we used raloxifene for many of our animal experiments. Significant RLUC activity was observed only in the site implanted with the stable cells expressing the mutant hER sensor (wild-type hER, 2.16 Ϯ 0.52 ϫ 10 3 photons per second per square centimeter per steradian; mutant hER, 9.7 Ϯ 1.2 ϫ 10 3 photons per second per square centimeter per steradian) (P Ͻ 0.01 relative to the site with wild-type hER) (Fig. 5a ). Similar FLUC activity pattern was observed with wild-type and mutant ER constructs (Figs. 11 and 12 ). The lower level of signal produced from implanted cells expressing the wild-type hER sensor is most likely due to competitive binding of endogenous estrogen before the availability of raloxifene. The split FLUC system showed significantly more signal in living animals than the same system with the RLUC fragments, so this sensor was used for studying the agonistand antagonist-specific induction of complementation in living mice.
Imaging of ER Intramolecular Folding Sensor to Distinguish ER Ligands
in Living Mice. We show the utility of our system in differentiating pharmacological classes of ER ligands in living animals based on receptor conformations by implanting 293T cells stably expressing the wild-type ER sensor (281-549) with FLUC fragments and the mutant form of ER-LBD (N-RLUC-hER 281-549/G521T -C-RLUC) on either side of the lower back of the male nude mice (n ϭ 2; two implants in each animal) and imaged 24 h after implantation (before ligand administration) and every 24 h after administration of 20 g of DES or 4-OHT with adjuvant (sesame oil) or adjuvant in a 50-l volume (17) . These results show a significantly greater level of complementation (P Ͻ 0.05) from animals that received the SERM than the animals that received the agonist or adjuvant only (Fig. 13 , which is published as supporting information on the PNAS web site).
Discussion
We have developed and validated two hER intramolecular folding sensors that can be used to distinguish ER ligand pharmacology. These receptor sensors can be directly translated from cell culture studies to molecular imaging in small living subjects. In this study we used an ER-based split reporter complementation strategy to follow the position of H12 within the ER-LBD to detect changes in the receptor structural folding in response to ligand binding. The longer construct with the F domain (281-595) appears ligandpharmacology-independent (Fig. 2b) , whereas the shorter con- struct without the F domain (281-549) leads to highest levels of split luciferase complementation in response to SERMs, moderate levels for agonists, and minimal levels for pure antiestrogens (Fig.  2c) . We validated these intramolecular folding sensors with various ER ligands in both transiently and stably transfected 293T cells and transiently transfected MDA-MB-231 (ER-negative) and MCF-7 (ER-positive) cells. To extend the folding sensor for applications in living animals, we incorporated a previously undescribed mutant of hER (G521T) into the folding sensor that was insensitive to circulating endogenous estrogen but retained its ability to distinguish SERMs from synthetic agonists. Alternatively, ovariectomized mice can likely be used with the wild-type hER with minimal competition from endogenous estrogens while retaining the ability to study estrogen-like drugs. Future studies should be performed to compare strategies with the wild-type and mutant systems.
To date, several in vitro assays have been developed for screening ER ligands by using either purified ER␣ protein or ER isolated from cell lysates (18) (19) (20) (21) . Limited fluorescence-based assays (22) have been developed to measure receptor conformational changes (23) and recruitment of coactivator peptides (22, 24, 25) in the full-length hER␣ within cell culture (26) . Other assays have been designed to study the effects of synthetic ligands on ER transcription through the activation of downstream target genes (27) . However, most of these reported assays are not suitable for quantitative, high-throughput screening of ER ligands in intact cells and especially in living subjects through noninvasive molecular imaging.
A nontranscriptional assay containing fusion chimeras of either Flp recombinase (28) or Cre recombinase (29) with a truncated mouse ER␣ (amino acids 281-599) has been reported and used for regulating the recombination of reporter genes in cells and living animals. This system demonstrates high background activity even before the addition of ER ligands, mainly through enzymatic amplification, thus limiting its dynamic range in response to different ER ligands. We developed an analogous fusion chimera by fusing a truncated version of hER (amino acids 281-595) with FLUC, which leads to luciferase activity that is 10 4 -fold greater than background (mock-transfected cells) even before the addition of ligands (unpublished data). The addition of ligands generates FLUC activity that is only 5-to 6-fold higher than that of carrier control-treated cells (unpublished data). These results clearly support the notion that these nontranscriptional chimeras containing ER-LBD are not optimal for studying concentration-dependent interactions between ER and their ligands.
To our knowledge, only one study has reported the construction of mutant versions of hER (G521R and G521V) for selective ER ligand binding using a fusion chimera containing hER 251-595 with Flp recombinase enzyme (28) . Incorporation of the same mutation into our intramolecular folding sensor (N-RLUC-hER 281-595 -C-RLUC) led to nearly complete abolishment of signal for all ER ligands (hER G521R ) and a significant reduction in signal (77-89%) for all agonist activities (hER G521V ) relative to hER G521G (P Ͻ 0.05) ( Table 1) . We constructed intramolecular folding sensors using the hER G521 mutants with 19 different possible amino acids. We found that the replacement of hER G521 with threonine leads to nearly complete abolishment of the E2-induced RLUC complementation and to only a 10-20% reduction for all other ER ligands studied. Subsequently, 293T cells stably expressing this intramolecular folding sensor (N-RLUC-hER 281-549/G521T -C-RLUC) were generated for imaging hER␣͞ligand complexes in living animals.
The advantages of the intramolecular folding sensor strategy developed and validated include the following: (i) it is real-time (because RLUC exhibits flash kinetics) and quantitative; (ii) it can be used to distinguish binding of agonists, SERMs, and pure antiestrogens; (iii) it can be adapted for studying ligand binding to hER in living animal models by molecular imaging, and thus pharmacokinetic properties of each drug͞ligand can be examined; (iv) it allows for a high-throughput strategy for screening͞ comparing different ER ligands and drugs in multiple cell lines; (v) it allows direct transition from cell culture studies to small living subjects because it is based on a bioluminescence split reporter strategy; and (vi) it will allow for applications using transgenic models that incorporate the intramolecular folding sensor. In addition, the availability of other split reporters with different properties and substrate specificity should allow multiplexing with other reporter assays.
The limitations with using split RLUC as the reporter gene regarding efflux of its substrate coelenterazine were resolved by showing experiments that resulted in no significant relation between the RLUC complementation and the multidrug resistance systems (Fig. 8) (11) . In addition, the intramolecular folding system was also studied with the improved split FLUC fragments by replacing RLUC fragments. Both systems showed equal sensitivity in different cell culture experiments. The FLUC fragments showed more detectable signal in mouse experiments than RLUC because of more light penetration through tissues due to the more redshifted wavelengths of FLUC. Also, the FLUC-based folding system showed greater efficiency in differentiating ER ligands in living mice. It is also possible that the exact locations (cytosolic vs. nuclear) of our fusion reporter proteins may affect the results obtained, and this will need to be explored in future studies. In addition, for some applications in vivo, the developed strategies may have difficult distinguishing agonists from background, and this will have to be investigated with testing of additional drugs.
The strategies developed in this study can also be extended to FRET and bioluminescence resonance energy transfer (30) by replacing the split RLUC͞FLUC reporter fragments with the appropriate choice of donors and acceptors. This system will help to validate a new class of molecular ''switch'' for imaging drugreceptor interactions in living subjects that was previously not feasible. This study will eventually translate to improved methods for understanding the underlying estrogen biology, preclinical drug development, and target validation, as well as investigation of other important intramolecular folding systems.
Methods
The methods used for constructing different plasmid vectors and the procedures used for cell culture, transfection, and luciferase assays for RLUC and FLUC are in Supporting Materials and Methods, which is published as supporting information on the PNAS web site (Figs. 2a and 6a) . 
